Cardiff Oncology to Present at May Investor Conferences

May 13, 2024 – Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company specializing in PLK1 inhibition to create innovative cancer treatments, has announced its participation in two investor conferences scheduled for May 2024. 

The first event is the H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking place at the Nasdaq Headquarters in New York City. This conference will feature a fireside chat presented by Mark Erlander, the CEO of Cardiff Oncology, on May 20, 2024, at 2:30 PM ET. The second event is the Cowen 5th Annual Oncology Innovation Summit, which will be held virtually. Mark Erlander will again represent the company in a fireside chat on May 29, 2024, at 1:30 PM ET.

Interested individuals can register for and watch the live webcasts of these events via the “Events” section of Cardiff Oncology’s website. Replay options will be available once the presentations conclude.

Cardiff Oncology focuses on developing pioneering cancer therapies by targeting PLK1, a well-validated protein linked to cancer progression. Their lead therapeutic candidate, onvansertib, is a PLK1 inhibitor currently under evaluation in combination with standard treatments for various cancers. These include RAS-mutated metastatic colorectal cancer (mCRC) and investigator-initiated trials for metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC). The aim of these programs is to address tumor vulnerabilities and enhance treatment efficacy beyond what standard care alone can achieve. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!